Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (48 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-11-08. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: uncontrolledchronic kidneyreceivingkidney diseasemalignancy
  Phrases that lowered it: type diabetesparticipantsagedcriteria patientsmellitus
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 60 (lowers risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 96.8% (raises risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Design: parallel (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Phase: 2/3 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 6 (raises risk) · Sponsor's track record
• Maximum age: 60 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin NCT03208309 · started 2013 · scored riskier than 14% of active trials completed
• Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects NCT02242149 · started 2014 · scored riskier than 18% of active trials completed
• A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise NCT05628311 · started 2023 · scored riskier than 28% of active trials completed
• A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU) NCT00723411 · started 2008 · scored riskier than 20% of active trials terminated
• A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT NCT00751842 · started 2008 · scored riskier than 12% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.